Asthma is a complex illness with a variety of symptoms and endotypes. As a result of unmet requirements in severe asthma, novel therapeutic targets beyond current medications have emerged. Several biologics have recently been studied, with several being licensed to treat T2 airway inflammation in individuals with severe illness. For a review, researchers overviewed newly authorized biologics, as well as those that are on the horizon, and pointed out unfulfilled needs in this field. Multiple biologics that target T2 high asthma were available for clinical use in severe patients with asthma who meet certain criteria. Allergy and eosinophilic asthma were among the characteristics that these drugs target. Exacerbations were reduced, and lung function was improved, according to available biologics. Improvements in patient-reported outcomes were also seen in some cases. Some of these biologics have also been shown to help with asthma-related comorbidities. Although only a few biomarkers exist, they can assist predict response to particular biologics. Emerging biologics were being developed to target various mechanisms of airway inflammation. Several small molecule inhibitors and antagonists were also being developed. There was a need for biologics and medicines that target T2 low or non-T2 asthma.

In a minority of individuals, recently authorized biological treatments enhanced asthma outcomes. Future research into improved predictors of response would help to increase the precision with which individuals with severe illness are treated.